蚌埠医学院学报
蚌埠醫學院學報
방부의학원학보
ACTA ACADEMIAE MEDICINAE BENGBU
2015年
6期
743-745
,共3页
心绞痛%瑞舒伐他汀钙%氯吡格雷
心絞痛%瑞舒伐他汀鈣%氯吡格雷
심교통%서서벌타정개%록필격뢰
angina pectoris%rosuvastatin calcium%clopidogrel
目的：：探讨瑞舒伐他汀钙与氯吡格雷联合治疗不稳定型心绞痛的临床疗效和安全性。方法：112例不稳定型心绞痛患者，根据治疗方法不同分为对照组和观察组。对照组44例给予低分子肝素、阿司匹林、血管紧张素转换酶抑制剂、硝酸酯类药物、β受体阻滞剂等常规治疗；观察组68例在对照组基础上给予瑞舒伐他汀钙联合氯吡格雷治疗，均治疗4周。观察2组临床疗效及安全性，并对血脂水平及不良反应情况进行监测。结果：观察组心绞痛症状改善总有效率为94.1%，高于对照组的81.8%(P<0.05)；观察组心电图改善总有效率为92.6%，显著高于对照组的77.3%(P<0.01)；2组治疗前血脂水平差异均无统计学意义(P>0.05)，治疗后2组血脂水平均较治疗前明显改善(P<0.01)；且治疗后2组血脂水平相比差异均有统计学意义(P<0.01)。观察组和对照组总不良反应发生率分别为2.9%与13.6%，差异无统计学意义(P>0.05)。随访期间，观察组心绞痛再发率低于对照组(P<0.05)。结论：在常规治疗基础上，瑞舒伐他汀钙与氯吡格雷联合治疗不稳定型心绞痛的临床疗效好，安全性高，值得临床应用。
目的：：探討瑞舒伐他汀鈣與氯吡格雷聯閤治療不穩定型心絞痛的臨床療效和安全性。方法：112例不穩定型心絞痛患者，根據治療方法不同分為對照組和觀察組。對照組44例給予低分子肝素、阿司匹林、血管緊張素轉換酶抑製劑、硝痠酯類藥物、β受體阻滯劑等常規治療；觀察組68例在對照組基礎上給予瑞舒伐他汀鈣聯閤氯吡格雷治療，均治療4週。觀察2組臨床療效及安全性，併對血脂水平及不良反應情況進行鑑測。結果：觀察組心絞痛癥狀改善總有效率為94.1%，高于對照組的81.8%(P<0.05)；觀察組心電圖改善總有效率為92.6%，顯著高于對照組的77.3%(P<0.01)；2組治療前血脂水平差異均無統計學意義(P>0.05)，治療後2組血脂水平均較治療前明顯改善(P<0.01)；且治療後2組血脂水平相比差異均有統計學意義(P<0.01)。觀察組和對照組總不良反應髮生率分彆為2.9%與13.6%，差異無統計學意義(P>0.05)。隨訪期間，觀察組心絞痛再髮率低于對照組(P<0.05)。結論：在常規治療基礎上，瑞舒伐他汀鈣與氯吡格雷聯閤治療不穩定型心絞痛的臨床療效好，安全性高，值得臨床應用。
목적：：탐토서서벌타정개여록필격뢰연합치료불은정형심교통적림상료효화안전성。방법：112례불은정형심교통환자，근거치료방법불동분위대조조화관찰조。대조조44례급여저분자간소、아사필림、혈관긴장소전환매억제제、초산지류약물、β수체조체제등상규치료；관찰조68례재대조조기출상급여서서벌타정개연합록필격뢰치료，균치료4주。관찰2조림상료효급안전성，병대혈지수평급불량반응정황진행감측。결과：관찰조심교통증상개선총유효솔위94.1%，고우대조조적81.8%(P<0.05)；관찰조심전도개선총유효솔위92.6%，현저고우대조조적77.3%(P<0.01)；2조치료전혈지수평차이균무통계학의의(P>0.05)，치료후2조혈지수평균교치료전명현개선(P<0.01)；차치료후2조혈지수평상비차이균유통계학의의(P<0.01)。관찰조화대조조총불량반응발생솔분별위2.9%여13.6%，차이무통계학의의(P>0.05)。수방기간，관찰조심교통재발솔저우대조조(P<0.05)。결론：재상규치료기출상，서서벌타정개여록필격뢰연합치료불은정형심교통적림상료효호，안전성고，치득림상응용。
Objective:To explore the curative effects and clinical safety of rosuvastatin calcium combined with clopidogrel in the treatment of unstable angina pectoris( UAP) . Methods:One hundred and twelve patients with UAP were divided into the control group (44 cases) and observation group(68 cases) according to different therapeutic methods. The control group and observation group were treated with low molecular heparin,aspirin,angiotensin converting enzyme inhibitors,nitrates and beta blockers and rosuvastatin calcium combined with clopidogrel based on the control group treatment,respectively. The clinical curative effects,safety,blood lipid level and adverse reactions in two groups were monitored. Results:The total effective rate in observation group(94. 1%) was higher than that in control group(81. 8%) (P < 0. 05). The effective rate of electrocardiogram improvement in observation group(92. 6%) was significantly higher than that in control group(77. 3%) (P<0. 01). The difference of the blood lipid level between two groups before treatment was not statistically significant (P >0. 05),the blood lipid level in observation group after treatment was improved(P <0.01),and the difference of the blood lipid level between two groups after treatment was statistically significant (P <0. 01). The incidences of adverse reactions in control group and observation group were 2. 9% and 13. 6%,respectively,the difference of which was not statistically significant (P>0. 05). During the following-up period,the angina recurrence rate in observation group were lower than those in controll group(P <0. 05). Conclusions:On the basis of conventional treatment,the rosuvastatin calcium combined with clopidogrel in the treatment of unstable angina pectoris has good effects and high safety,which is worthy of clinical application.
